Published in Clin Exp Immunol on May 18, 2011
Indoleamine 2,3-dioxygenase and dendritic cell tolerogenicity. Immunol Invest (2012) 1.05
Induction of indoleamine 2,3-dioxygenase by uropathogenic bacteria attenuates innate responses to epithelial infection. J Infect Dis (2012) 0.95
Mycobacterium leprae intracellular survival relies on cholesterol accumulation in infected macrophages: a potential target for new drugs for leprosy treatment. Cell Microbiol (2014) 0.93
New Insights into IDO Biology in Bacterial and Viral Infections. Front Immunol (2014) 0.92
Lessons of leprosy: the emergence of TH17 cytokines during type II reactions (ENL) is teaching us about T-cell plasticity. J Drugs Dermatol (2012) 0.84
Interleukin-10-dependent down-regulation of interferon-gamma response to Leishmania by Mycobacterium leprae antigens during the clinical course of a coinfection. Braz J Med Biol Res (2012) 0.80
Microorganisms linked to inflammatory bowel disease-associated dysbiosis differentially impact host physiology in gnotobiotic mice. ISME J (2015) 0.80
Increased frequency of CD4 and CD8 regulatory T cells in individuals under 15 years with multibacillary leprosy. PLoS One (2013) 0.79
Effect of apoptotic cell recognition on macrophage polarization and mycobacterial persistence. Infect Immun (2014) 0.78
Induction of indoleamine 2,3-dioxygenase by Borrelia burgdorferi in human immune cells correlates with pathogenic potential. J Leukoc Biol (2014) 0.75
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods (2001) 414.27
Exploring the full spectrum of macrophage activation. Nat Rev Immunol (2008) 26.08
Classification of leprosy according to immunity. A five-group system. Int J Lepr Other Mycobact Dis (1966) 22.28
Massive gene decay in the leprosy bacillus. Nature (2001) 11.98
Prevention of allogeneic fetal rejection by tryptophan catabolism. Science (1998) 9.80
Defining protective responses to pathogens: cytokine profiles in leprosy lesions. Science (1991) 8.85
Genomewide association study of leprosy. N Engl J Med (2009) 8.17
Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest (2007) 5.05
Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science (1995) 4.85
Post-transcriptional control of cytokine production. Nat Immunol (2008) 3.30
T cell apoptosis by tryptophan catabolism. Cell Death Differ (2002) 3.07
Macrophages as APC and the dendritic cell myth. J Immunol (2008) 2.90
TLR activation triggers the rapid differentiation of monocytes into macrophages and dendritic cells. Nat Med (2005) 2.62
Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape. Immunol Rev (2008) 2.47
Simultaneous measurement of serum tryptophan and kynurenine by HPLC. Clin Chem (1997) 2.39
Interferon-gamma and tumor necrosis factor-alpha mediate the upregulation of indoleamine 2,3-dioxygenase and the induction of depressive-like behavior in mice in response to bacillus Calmette-Guerin. J Neurosci (2009) 2.22
Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase. Proc Natl Acad Sci U S A (2008) 2.18
Cellular responses to the intradermal injection of recombinant human gamma-interferon in lepromatous leprosy patients. Am J Pathol (1987) 2.18
Immunosuppressive roles for IL-10 and IL-4 in human infection. In vitro modulation of T cell responses in leprosy. J Immunol (1993) 2.00
Human anti-inflammatory macrophages induce Foxp3+ GITR+ CD25+ regulatory T cells, which suppress via membrane-bound TGFbeta-1. J Immunol (2008) 1.91
Lipid droplet formation in leprosy: Toll-like receptor-regulated organelles involved in eicosanoid formation and Mycobacterium leprae pathogenesis. J Leukoc Biol (2009) 1.89
IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism. Cancer Immunol Immunother (2008) 1.88
Leprosy type 1 (reversal) reactions and their management. Lepr Rev (2008) 1.81
TNF-alpha is a critical negative regulator of type 1 immune activation during intracellular bacterial infection. J Clin Invest (2004) 1.76
Patterns of cytokine production by mycobacterium-reactive human T-cell clones. Infect Immun (1993) 1.72
Differentiation and heterogeneity in the mononuclear phagocyte system. Mucosal Immunol (2008) 1.70
Prolonged treatment with recombinant interferon gamma induces erythema nodosum leprosum in lepromatous leprosy patients. J Exp Med (1992) 1.63
Indoleamine 2,3-dioxygenase-expressing dendritic cells form suppurative granulomas following Listeria monocytogenes infection. J Clin Invest (2006) 1.58
Suppressor T lymphocytes from lepromatous leprosy skin lesions. J Immunol (1986) 1.55
An analysis of in vitro T cell responsiveness in lepromatous leprosy. J Exp Med (1985) 1.52
Intratumoral immune cell infiltrates, FoxP3, and indoleamine 2,3-dioxygenase in patients with melanoma undergoing CTLA4 blockade. Clin Cancer Res (2009) 1.49
T cell apoptosis by kynurenines. Adv Exp Med Biol (2003) 1.43
IL-17 and therapeutic kynurenines in pathogenic inflammation to fungi. J Immunol (2008) 1.40
Indoleamine 2,3-dioxygenase in infection: the paradox of an evasive strategy that benefits the host. Microbes Infect (2008) 1.39
Granulomatous reaction to intradermal injection of lepromin (Mitsuda reaction) is linked to the human NRAMP1 gene in Vietnamese leprosy sibships. J Infect Dis (2000) 1.25
Towards a genetic definition of cancer-associated inflammation: role of the IDO pathway. Am J Pathol (2010) 1.24
IDO: a double-edged sword for T(H)1/T(H)2 regulation. Immunol Lett (2008) 1.21
IDO-expressing regulatory dendritic cells in cancer and chronic infection. J Mol Med (Berl) (2007) 1.18
Post-translational regulation of human indoleamine 2,3-dioxygenase activity by nitric oxide. J Biol Chem (2007) 1.16
Heme oxygenase-1, carbon monoxide, and bilirubin induce tolerance in recipients toward islet allografts by modulating T regulatory cells. FASEB J (2007) 1.14
Restriction of Toxoplasma gondii growth in human brain microvascular endothelial cells by activation of indoleamine 2,3-dioxygenase. Infect Immun (2001) 1.11
Natural emergence of antigen-reactive T cells in lepromatous leprosy patients during erythema nodosum leprosum. Infect Immun (1985) 1.10
Cytokine mRNA expression in leprosy: a possible role for interferon-gamma and interleukin-12 in reactions (RR and ENL). Scand J Immunol (1999) 1.09
Enhanced indoleamine 2,3-dioxygenase activity in patients with severe sepsis and septic shock. J Infect Dis (2010) 1.02
Role of macrophages in defective cell mediated immunity in lepromatous leprosy. I. Factor(s) from macrophages affecting protein synthesis and lymphocyte transformation. Int J Lepr Other Mycobact Dis (1980) 1.01
Indoleamine 2,3-dioxigenase (IDO) is critical for host resistance against Trypanosoma cruzi. FASEB J (2010) 0.94
Indoleamine 2,3-dioxygenase (IDO): the antagonist of type I interferon-driven skin inflammation? Am J Pathol (2007) 0.92
Modulation of indoleamine-2,3-dioxygenase expression and activity by HIV-1 in human macrophages. Fundam Clin Pharmacol (2009) 0.89
Induction of apoptosis in monocytes by Mycobacterium leprae in vitro: a possible role for tumour necrosis factor-alpha. Immunology (2003) 0.88
The effect of antigen presenting cells on the cytokine profiles of stable and reactional lepromatous leprosy patients. Immunol Lett (2000) 0.87
Increased activity of indoleamine 2,3-dioxygenase in serum from acutely infected dengue patients linked to gamma interferon antiviral function. J Gen Virol (2009) 0.86
Long-term culture of multibacillary leprosy macrophages isolated from skin lesions: a new model to study Mycobacterium leprae-human cell interaction. Br J Dermatol (2007) 0.83
Tumor necrosis factor-alpha promoter polymorphism TNF2 is associated with a stronger delayed-type hypersensitivity reaction in the skin of borderline tuberculoid leprosy patients. Immunogenetics (2001) 0.81
Macrophages and the regulation of self-reactive T cells. Curr Pharm Des (2003) 0.81
Expression of cyclooxygenase type 2 in lepromatous and tuberculoid leprosy lesions. Br J Dermatol (2003) 0.80
Utilization of superoxide anion by indoleamine oxygenase-catalyzed tryptophan and indoleamine oxidation. Adv Exp Med Biol (1996) 0.80
The proteasome function is required for Mycobacterium leprae-induced apoptosis and cytokine secretion. Immunol Lett (2007) 0.78
Indoleamine 2,3-dioxygenase--a new antioxidant enzyme. Mater Med Pol (1991) 0.77
Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med (1991) 4.43
The cutaneous infiltrates of leprosy: cellular characteristics and the predominant T-cell phenotypes. N Engl J Med (1982) 3.52
Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med (1993) 3.31
Defective gamma interferon production in leprosy. Reversal with antigen and interleukin 2. J Exp Med (1983) 2.61
Cellular responses to the intradermal injection of recombinant human gamma-interferon in lepromatous leprosy patients. Am J Pathol (1987) 2.18
Influence of delayed immune reactions on human epidermal keratinocytes. Proc Natl Acad Sci U S A (1986) 2.11
Prolonged treatment with recombinant interferon gamma induces erythema nodosum leprosum in lepromatous leprosy patients. J Exp Med (1992) 1.63
The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. J Infect Dis (1993) 1.55
The cutaneous infiltrates of leprosy. A transmission electron microscopy study. J Exp Med (1983) 1.51
[Progression to IDDM and islet cell antibodies (ICA; ICA-CF)]. J Pediatr (Rio J) (2003) 1.39
Use of ML dipstick as a tool to classify leprosy patients. Int J Lepr Other Mycobact Dis (2000) 1.16
Cytokine gene activation and modified responsiveness to interleukin-2 in the blood of tuberculosis patients. J Infect Dis (1993) 1.12
Cellular immune response to Mycobacterium leprae infection in human immunodeficiency virus-infected individuals. Infect Immun (1995) 1.10
Immunological cytokine correlates of protective immunity and pathogenesis in leprosy. Scand J Immunol (2000) 1.10
Cytokine mRNA expression in leprosy: a possible role for interferon-gamma and interleukin-12 in reactions (RR and ENL). Scand J Immunol (1999) 1.09
Reactional states in multibacillary Hansen disease patients during multidrug therapy. Rev Inst Med Trop Sao Paulo (1999) 1.09
Interleukin-10 promoter single-nucleotide polymorphisms as markers for disease susceptibility and disease severity in leprosy. Genes Immun (2004) 1.02
Use of PCR-mediated amplification of Mycobacterium leprae DNA in different types of clinical samples for the diagnosis of leprosy. J Med Microbiol (1993) 1.01
[Leprosy epidemiology in a cohort of household contacts in Rio de Janeiro (1987-1991)]. Cad Saude Publica (2000) 0.99
IFNG +874 T>A single nucleotide polymorphism is associated with leprosy among Brazilians. Hum Genet (2010) 0.99
HeLp, a heme lipoprotein from the hemolymph of the cattle tick, Boophilus microplus. J Biol Chem (2000) 0.97
Pentoxifylline decreases in vivo and in vitro tumour necrosis factor-alpha (TNF-alpha) production in lepromatous leprosy patients with erythema nodosum leprosum (ENL). Clin Exp Immunol (1998) 0.96
Serological response of patients with leprosy to a 28- to 30-kilodalton protein doublet from early cultures of Mycobacterium bovis BCG. J Clin Microbiol (1989) 0.96
HLA-DRB1*04 and DRB1*10 are associated with resistance and susceptibility, respectively, in Brazilian and Vietnamese leprosy patients. Genes Immun (2007) 0.94
T cell immune responses to mycobacterial antigens in Brazilian tuberculosis patients and controls. Trans R Soc Trop Med Hyg (2005) 0.92
Bacterial and host-derived cationic proteins bind alpha2-laminins and enhance Mycobacterium leprae attachment to human Schwann cells. Microbes Infect (2000) 0.92
M. leprae-HIV co-infection: pattern of immune response in vivo and in vitro. Indian J Lepr (2000) 0.92
Serology and leprosy: immunoassays comparing immunoglobulin G antibody responses to 28- and 30-kilodalton proteins purified from Mycobacterium bovis BCG. J Clin Microbiol (1991) 0.91
Neutrophils isolated from leprosy patients release TNF-alpha and exhibit accelerated apoptosis in vitro. J Leukoc Biol (1999) 0.89
Management of erythema nodosum leprosum by thalidomide: thalidomide analogues inhibit M. leprae-induced TNFalpha production in vitro. Biomed Pharmacother (2002) 0.89
Immunotherapy against visceral leishmaniasis with the nucleoside hydrolase-DNA vaccine of Leishmania donovani. Vaccine (2006) 0.89
Binding of alpha2-laminins by pathogenic and non-pathogenic mycobacteria and adherence to Schwann cells. J Med Microbiol (2001) 0.89
Immunological responsiveness to M. leprae and BCG antigens in 98 leprosy patients and their household contacts. Braz J Med Biol Res (1988) 0.89
Effectiveness of BCG vaccination among leprosy contacts: a cohort study. Trans R Soc Trop Med Hyg (2008) 0.89
Effect of treatment on the cellular composition of cutaneous lesions in leprosy patients. Int J Lepr Other Mycobact Dis (1984) 0.89
Induction of apoptosis in monocytes by Mycobacterium leprae in vitro: a possible role for tumour necrosis factor-alpha. Immunology (2003) 0.88
Trypanosoma cruzi: the effect of variations in experimental conditions on the levels of macrophage infection in vitro. Parasitol Res (1989) 0.87
Thalidomide protects mice against LPS-induced shock. Braz J Med Biol Res (1997) 0.87
DC-SIGN association with the Th2 environment of lepromatous lesions: cause or effect? J Pathol (2006) 0.87
Influence of Mycobacterium leprae and its soluble products on the cutaneous responsiveness of leprosy patients to antigen and recombinant interleukin 2. Proc Natl Acad Sci U S A (1989) 0.86
High prevalence of vasomotor reflex impairment in newly diagnosed leprosy patients. Eur J Clin Invest (2005) 0.86
Sequential erythema nodosum leprosum and reversal reaction with similar lesional cytokine mRNA patterns in a borderline leprosy patient. Br J Dermatol (2001) 0.86
An immunohistochemical, clinical and electroneuromyographic correlative study of the neural markers in the neuritic form of leprosy. Braz J Med Biol Res (2006) 0.86
Anti-inflammatory drugs block cytokine mRNA accumulation in the skin and improve the clinical condition of reactional leprosy patients. J Invest Dermatol (2000) 0.85
Effect of unique Mycobacterium leprae phenolic glycolipid-I (PGL-I) on tumour necrosis factor production by human mononuclear cells. Lepr Rev (2001) 0.85
Double-blind trial of the efficacy of pentoxifylline vs thalidomide for the treatment of type II reaction in leprosy. Braz J Med Biol Res (2007) 0.84
Expression and cytokine secretion in the states of immune reactivation in leprosy. Braz J Med Biol Res (1998) 0.83
In vitro tumor necrosis factor production by mononuclear cells from lepromatous leprosy patients and from patients with erythema nodosum leprosum. Clin Immunol Immunopathol (1993) 0.83
Long-term culture of multibacillary leprosy macrophages isolated from skin lesions: a new model to study Mycobacterium leprae-human cell interaction. Br J Dermatol (2007) 0.83
Mycobacterium leprae-induced interferon-gamma production by household contacts of leprosy patients: association with the development of active disease. J Infect Dis (1991) 0.83
Patterns of intracellular cytokines in CD4 and CD8 T cells from patients with mycobacterial infections. Braz J Med Biol Res (2004) 0.82
Different immunosuppressive mechanisms in multi-drug-resistant tuberculosis and non-tuberculous mycobacteria patients. Clin Exp Immunol (2013) 0.82
Detection of in vitro interferon-gamma and serum tumour necrosis factor-alpha in multidrug-resistant tuberculosis patients. Clin Exp Immunol (2005) 0.82
Impairments in multibacillary leprosy; a study from Brazil. Lepr Rev (2004) 0.81
Effect of treatment on immune responsiveness in lepromatous leprosy patients. Lepr Rev (1990) 0.81
Topical S-nitrosoglutathione-releasing hydrogel improves healing of rat ischaemic wounds. J Tissue Eng Regen Med (2010) 0.81
Tumor necrosis factor-alpha promoter polymorphism TNF2 is associated with a stronger delayed-type hypersensitivity reaction in the skin of borderline tuberculoid leprosy patients. Immunogenetics (2001) 0.81
T-helper cell subpopulations and the immune spectrum of leprosy. Int J Lepr Other Mycobact Dis (1989) 0.80
The use of pentoxifylline in the treatment of type 2 reactional episodes in leprosy. Indian J Lepr (2001) 0.80
Increased Langerhans cell accumulation after mycobacterial stimuli. Histopathology (2007) 0.80
Further biochemical characterization of Mycobacterium leprae laminin-binding proteins. Braz J Med Biol Res (2001) 0.79
Development of giant reaction in response to PPD skin test in lepromatous leprosy patients. Int J Lepr Other Mycobact Dis (1993) 0.79
Tumor necrosis factor promoter polymorphism (TNF2) seems to protect against development of severe forms of leprosy in a pilot study in Brazilian patients. Int J Lepr Other Mycobact Dis (2000) 0.79
The diagnosis of leprosy among patients with symptoms of peripheral neuropathy without cutaneous lesions: a follow-up study. Arq Neuropsiquiatr (2000) 0.79
Interferon alpha treatment of patients with impaired interferon gamma signaling. J Clin Immunol (2013) 0.79
Two multidrug fixed-dosage treatment regimens with multibacillary leprosy patients. Indian J Lepr (1997) 0.78
Is pentoxifylline a viable alternative in the treatment of ENL? Int J Lepr Other Mycobact Dis (1995) 0.78
Distribution of mononuclear phagocytes in glomerulonephritis with crescents. Nephron (1982) 0.78
Experimental Mycobacterium leprae infection in BALB/c mice: effect of BCG administration on TNF-alpha production and granuloma development. Int J Lepr Other Mycobact Dis (2000) 0.78
The role of inflammatory cytokines in the tissue injury of leprosy. Int J Lepr Other Mycobact Dis (1996) 0.78
The effect of thalidomide on BCG-induced granulomas in mice. Braz J Med Biol Res (1995) 0.78
Tumor necrosis factor (TNF) and lymphotoxin-alpha (LTA) single nucleotide polymorphisms: importance in ARDS in septic pediatric critically ill patients. Hum Immunol (2012) 0.78
Pathogenesis of nerve damage in leprosy: genetic polymorphism regulates the production of TNF alpha. Lepr Rev (2000) 0.78
CD123, the plasmacytoid dendritic cell phenotypic marker, is abundant in leprosy type 1 reaction. Br J Dermatol (2014) 0.77
Trypanosoma cruzi: plasma levels of alpha-2-macroglobulin during experimental murine infections with reticulotropic and myotropic strains. Parasitol Res (1990) 0.77
Search for evidence of a Th2 profile in HIV+ patients. Int J Dermatol (2000) 0.77